Trial
NCT03630055
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Ottawa Heart Institute Research Corporation
Collaborators
—
Condition
Radial Artery Occlusion
Intervention
Rivaroxaban 15 MG Oral Tablet [Xarelto]
Why stopped
Assessment for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-05